Brief: Agios announces topline results from RISE UP phase 3 trial of Mitapivat in sickle cell disease

Agios Pharmaceuticals

19/11/2025 12:26

Nov 19 (Reuters) - Agios Pharmaceuticals Inc AGIO.O:

AGIOS ANNOUNCES TOPLINE RESULTS FROM RISE UP PHASE 3 TRIAL OF MITAPIVAT IN SICKLE CELL DISEASE

AGIOS ANNOUNCES TOPLINE RESULTS FROM RISE UP PHASE 3 TRIAL OF MITAPIVAT IN SICKLE CELL DISEASE

AGIOS PHARMACEUTICALS INC - TRIAL MEETS PRIMARY AND KEY SECONDARY ENDPOINTS

AGIOS : TRIAL SHOWED TREND FAVORING MITAPIVAT BUT DID NOT MEET STATISTICAL SIGNIFICANCE IN PRIMARY ENDPOINT OF ANNUALIZED RATE OF SCPCS

AGIOS PHARMACEUTICALS INC - MITAPIVAT SAFETY PROFILE CONSISTENT WITH PRIOR TRIALS

AGIOS PHARMACEUTICALS INC - PLANS SNDA MEETING WITH FDA FOR MITAPIVAT IN Q1 2026

Source text: nGNXwMfCG

Further company coverage: AGIO.O

 ((Reuters.Briefs@thomsonreuters.com;))